Table 1 –

Scoping Review Results Categorized by Participants and Gait Analysis.

Author (year)	Study Type	Participant Characteristics*	Timing of Gait Analysis	Type of Gait Analysis	Primary Results
Gilchrist et al. (2016) 20	Prospective Observation	N = 52 Sex: 30 females; 22 males Age: 11.3 ± 4.5 years Control: 52 (11.3 ± 4.5 years) Cancer Types: ALL (44%), Hodgkin or non-Hodgkin lymphoma (35%), non-CNS solid tumor (21%) Chemotherapy: Vincristine (all patients, mean cumulative dose of 17.5 ± 8.8 mg/m2), methotrexate (30 patients, mean cumulative dose of 132.3 mg), vinblastine (4 patients, mean cumulative dose of 18.8 mg/m2)	ALL patients tested: end of delayed intensification stage (~ 6 months into treatment) Hodgkin or non-Hodgkin lymphoma or other solid tumors tested: end of treatment (~3-6 months into treatment) Average time in treatment: 6.1 ± 2.4 months Other: Each patient’s gait was tested before and after a 6 Minute Walk Test (6MWT)	Instrumented Gait Analysis: (GaitRite electronic walkway) velocity (cm/s) cadence (steps/min) step length (cm) base of support (cm) time in double support (percent of the cycle) percent of time each portion of the foot is in contact with the pressure mat	Slower walking velocity in oncology participant compared to healthy children due to a decreased step length and wider base of support Tightness in ankle dorsiflexion helps explain variances
Beulertz et al. (2016) 21	Cross-sectional	N = 13 Sex: 8 females; 5 males Age: 11.14 ± 3.53 years Control: 13 (11.29 ± 3.42 years) Cancer Types: ALL (30.8%), Hodgkin or non-Hodgkin lymphoma (15.4%), CNS tumor (23.1%), non-CNS solid tumor (30.8%) Chemotherapy: 10 of out 11 participants that utilized chemotherapy agents had received vincristine during medical treatment (doses not specified)	After completion of chemotherapy Mean time since cessation of medical Treatment = 1.37 ± 1.07 years Mean age at diagnosis 9.30 ± 4.20 years	Instrumented Gait Analysis: Microgate Optogait 2D Gait Analysis System: length parameters in centimeters (step length, stride length, step width) gait cycle parameters in percentage (stance phase, swing phase, single-limb support, double-limb support, loading response, and pre swing phase) time parameters in seconds (step time and gait cycle), and cadence (steps per min) and walking speed in meters per second.	Decreased dorsiflexion range of motion in oncology sample compared to healthy children in both knee flexed and extended positions Significant differences in stance, swing, and preswing phase
Wright et al. (2017) 22	Cross-sectional	N = 17 Sex: 10 females; 7 males Age: 11.2 ± 5.7 years Control: 10 (12.4 ± 5.5 years) Cancer Types: ALL Chemotherapy: Vincristine (doses 1.5 mg/m2 weekly during induction and 2.0 mg/m2 every three weeks during consolidation and maintenance therapy)	7 subjects were tested during continuation treatment 10 subjects were tested after completion of treatment Average time off treatment: 35.7 ± 28.5 months	Instrumented: 3-DMA: VICON 8 MX-40 camera system (Vicon Motion Systems Inc.) Gait: Plug-in-Gait 16 marker set (2.0.1), Polygon software (Version 3.1) and Plug-in-Gait 16 marker set (2.0.1), Polygon software (Version 3.1), and three 1000 Hz force platforms Advanced Mechanical Technology Inc. Video Analysis: 2 synchronized video cameras Electromyography (EMG): surface, gastrocnemius and tibialis anterior muscles	significantly less dorsiflexion at initial contact significantly shorter step lengths and slower velocities compared to the control group

ALL – acute lymphoblastic leukemia CNS – central nervous system

^*The demographic data in the table was reformatted to allow for easier comparisons including converting percentages to numeric values. None of the information was altered in a way as to change the data from the studies included.